Publikation:
Human Biomonitoring Initiative (HBM4EU): Human Biomonitoring Guidance Values Ddived for dmethylformamide

Kurzanzeige
dc.contributor.authorLamkarkach, Farida
dc.contributor.authorApel, Petra
dc.contributor.authorMeslin, Matthieu
dc.contributor.authorKolossa-Gehring, Marike
dc.date.accessioned2024-06-16T13:10:58Z
dc.date.available2024-06-16T13:10:58Z
dc.date.issued2022
dc.description.abstractWithin the European Joint Program on Human Biomonitoring HBM4EU, human biomonitoring guidance values (HBM-GVs) for the general population (HBM-GVGenPop) or for occupationally exposed adults (HBM-GVWorker) are derived for prioritized substances including dimethylformamide (DMF). The methodology to derive these values that was agreed upon within the HBM4EU project was applied. A large database on DMF exposure from studies conducted at workplaces provided dose-response relationships between biomarker concentrations and health effects. The hepatotoxicity of DMF has been identified as having the most sensitive effect, with increased liver enzyme concentrations serving as biomarkers of the effect. Out of the available biomarkers of DMF exposure studied in this paper, the following were selected to derive HBM-GVWorker: total N-methylformamide (tNMF) (sum of N-hydroxymethyl-N-methylformamide and NMF) and N-acetyl-S-(N-methylcarbamoyl)cysteine (AMCC) in urine. The proposed HBM-GVWorker is 10 mgL-1 or 10 mgg-1 creatinine for both biomarkers. Due to their different half-lives, tNMF (representative of the exposure of the day) and AMCC (representative of the preceding days' exposure) are complementary for the biological monitoring of workers exposed to DMF. The levels of confidence for these HBM-GVWorker are set to "high" for tNMF and "medium-low" for AMCC. Therefore, further investigations are required for the consolidation of the health-based HBM-GV for AMCC in urine. © 2022 by the authorsen
dc.format.extent1 Onlineresource (25 pages
dc.format.mediumonline resource
dc.identifier.doihttps://doi.org/10.60810/openumwelt-193
dc.identifier.urihttps://openumwelt.de/handle/123456789/2640
dc.language.isoeng
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/
dc.subjectRichtwert
dc.subjectBiomarker
dc.subjectHuman-Biomonitoring
dc.subjectPharmakokinetik
dc.subjectGesundheitliche Auswirkungen
dc.subjectLeber
dc.subjectKanzerogenität
dc.titleHuman Biomonitoring Initiative (HBM4EU): Human Biomonitoring Guidance Values Ddived for dmethylformamide
dc.typeWissenschaftlicher Artikel
dc.type.dcmitext
dc.type.mediumcomputer
dspace.entity.typePublication
local.bibliographicCitation.journalTitleToxics
local.bibliographicCitation.originalDOI10.3390/toxics10060298
local.bibliographicCitation.volume10 (2022), Heft 6
local.collectionAufsätze
local.contributor.authorId02186371
local.contributor.authorId02190313
local.identifier.catalogId02492619
local.ingest.leader06333naa a2200000uu 4500
local.jointTitleHUMAN BIOMONITORING INITIATIVE HBM4EU HUMAN BIOMONITORING GUIDANCE VALUES DDIVED FOR DMETHYLFORMAMIDE
local.reviewtrue
local.sourcecatalog
local.source.urihttp://creativecommons.org/licenses/by/4.0/deed.de
local.staffPublicationtrue
relation.isAuthorOfPublication28f9b1e3-5211-44ba-8d52-c462cd5fe32d
relation.isAuthorOfPublication0c3b6c3e-eff4-42d8-94e9-07a4fee4049c
relation.isAuthorOfPublication.latestForDiscovery28f9b1e3-5211-44ba-8d52-c462cd5fe32d
Dateien
Sammlungen
Aufsätze